Information Provided By:
Fly News Breaks for April 12, 2017
TROV
Apr 12, 2017 | 12:34 EDT
Maxim analyst Jason McCarthy upgraded Trovagene to Buy intraday after downgrading the stock to Hold on March 16. In-licensing a small molecule oncology drug from Nerviano Medical Sciences marks a new chapter for the company in precision cancer therapeutics, McCarthy tells investors in a research note. The analyst set a $4 price target for the shares. Trovagene in midday trading is up 15% to 87c.
News For TROV From the Last 2 Days
There are no results for your query TROV
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.